In-Depth Examination Of 16 Analyst Recommendations For Ecolab
Throughout the last three months, 16 analysts have evaluated Ecolab (NYSE:ECL), offering a diverse set of opinions from…
Ecolab Life Sciences And Repligen Launch DurA Cycle Affinity Resin For Large-Scale Biologic Manufacturing
Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of
How Is The Market Feeling About Ecolab?
Ecolab’s (NYSE:ECL) short percent of float has risen 34.67% since its last report. The company recently reported that…
What 15 Analyst Ratings Have To Say About Ecolab
15 analysts have shared their evaluations of Ecolab (NYSE:ECL) during the recent three months, expressing a mix of…
Jim Cramer Says This Materials Stock Is A ‘Great Spec,’ Plus He Recommends Buying Abercrombie & Fitch
CNBC's Jim Cramer recommends buying Abercrombie & Fitch (ANF). Taseko Mines (TGB) is a good speculative buy, he says.
Ecolab and HeiQ Launched Synbiotic Cleaning Products at Interclean in Amsterdam, The Netherlands
Ecolab and HeiQ Chrisal have teamed up to launch the revolutionary Maxx Synbiotic cleaning range at Interclean in Amsterdam, The Netherlands.
Ecolab, a global sustainability leader offering water, hygiene,
Jim Cramer Says Buy This Tech Stock Right Here, Likes Cognex
Cramer recommends buying Cloudflare after the company reported upbeat earnings for its first quarter and issued 2024 guidance below estimates.
The Analyst Landscape: 20 Takes On Ecolab
20 analysts have shared their evaluations of Ecolab (NYSE:ECL) during the recent three months, expressing a mix of…
Ecolab Gains After Beating Q1 Sales Expectations And Raising FY24 Outlook; Divests Surgical Segment For $950M
Ecolab surges post-Q1 with sales beat, raised FY24 outlook, and plans to sell surgical segment for $950M cash.
Ecolab Returning As A Consistent Earnings Compounder, Says Analyst
Ecolab receives a bullish boost as Mizuho analyst John Roberts upgrades its shares from Neutral to Buy, elevating the price target to $260 from $216. Roberts notes ECL's return to historical performance trends, with nearly 25 years of meeting or surpassing quarterly estimates pre-pandemic.